Latest News
Novel Approaches in Hypoparathyroidism Management
1 minutes ago
In ‘Novel Approaches in Hypoparathyroidism Management,’ our experts delve into novel treatment options for patients who are inadequately controlled on conventional therapy and the mechanism of action of palopegteriparatide.
Challenges of Conventional Therapy in Hypoparathyroidism
6 minutes ago
In this episode, ‘Challenges of Conventional Therapy in Hypoparathyroidism,’ the expert endocrinologists explore conventional therapy for chronic hypoparathyroidism, symptom control, and the risk of complications.
Quality of Life Impact in Hypoparathyroidism
11 minutes ago
In ‘Acute and Long-Term Complications of Hypoparathyroidism,’ our panel delves into the potential renal, neuromuscular, cognitive, and bone complications that impact patients.
Acute and Long-Term Complications of Hypoparathyroidism
16 minutes ago
In ‘Acute and Long-Term Complications of Hypoparathyroidism,’ our panel delves into the potential renal, neuromuscular, cognitive, and bone complications that impact patients. Led by the moderator, Dr. Kohlmeier, the expert panel, Dr. Rubin, Dr. Warren, and Dr. Al-Dallal, examines the following critical questions: 1. How is hypoparathyroidism diagnosed? 2. What are the key challenges in both diagnosing and monitoring patients with hypoparathyroidism? Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward. The next episode in this series, ‘Acute and Long-Term Complications of Hypoparathyroidism,’ features the panelists advancing their conversation on hypoparathyroidism and focusing on the potential renal, neuromuscular, cognitive, and bone complications that impact patients.
Future Directions in ATTR-CM
16 minutes ago
The panel concludes by discussing the future of ATTR-CM care. They highlight continued progress in disease-modifying therapies, with growing interest in determining how best to sequence or potentially combine treatments as evidence evolves. The group notes that as patients are diagnosed earlier, the goals of therapy may increasingly shift from slowing decline to preserving long-term function and quality of life. They emphasize the importance of expanding awareness and education across specialties so that more patients are recognized before advanced cardiac dysfunction develops. Improving access to therapy remains an essential area of focus, as cost and insurance barriers continue to influence treatment decisions. The panel also anticipates advances in monitoring disease progression, including the use of biomarkers and imaging to better assess response over time. Ultimately, the experts express optimism that ongoing research, broader recognition, and more refined care pathways will continue to improve outcomes for individuals living with ATTR-CM.